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ed March 13, 2013.he aim of this study was to assess the potential beneﬁts of inorganic nitrite in 2 clinical models: stress-induced
myocardial ischemia and whole-arm ischemia-reperfusion.Background Inorganic nitrite, traditionally considered a relatively inert metabolite of nitric oxide, may exert vasomodulatory and
vasoprotective effects. Despite promising results from animal models, few have shown effectiveness in human
model systems, and none have fully translated to the clinical setting.Methods In 10 patients with inducible myocardial ischemia, saline and low-dose sodium nitrite (NaNO2) (1.5 mmol/min for
20 min) were administered in a double-blind fashion during dobutamine stress echocardiography, at separate visits
and in a random order; long-axis myocardial function was quantiﬁed by peak systolic velocity (Vs) and strain rate
(SR) responses. In 19 healthy subjects, ﬂow-mediated dilation was assessed before and after whole-arm ischemia-
reperfusion; nitrite was given before ischemia or during reperfusion.Results Comparing saline and nitrite infusions, Vs and SR at peak dobutamine increased in regions exhibiting ischemia
(Vs from 9.5  0.5 cm/s to 12.4  0.6 cm/s, SR from 2.0  0.2 s1 to 2.8  0.3 s1), whereas they did not
change in normally functioning regions (Vs from 12.6  0.4 cm/s to 12.6  0.6 cm/s, SR from 2.6  0.3 s1 to
2.3  0.1 s1) (p < 0.001, analysis of variance). With NaNO2, the increment of Vs (normalized for increase in
heart rate) increased only in poorly functioning myocardial regions (þ122%, p < 0.001). Peak ﬂow-mediated dilation
decreased by 43% after ischemia-reperfusion when subjects received only saline (6.8  0.7% vs. 3.9  0.7%, p <
0.01); administration of NaNO2 before ischemia prevented this decrease in ﬂow-mediated dilation (5.9  0.7% vs.
5.2  0.5%, p ¼ NS), whereas administration during reperfusion did not.Conclusions Low-dose NaNO2 improves functional responses in ischemic myocardium but has no effect on normal regions.
Low-dose NaNO2 protects against vascular ischemia-reperfusion injury only when it is given before the onset of
ischemia. (J Am Coll Cardiol 2013;61:2534–41) ª 2013 by the American College of Cardiology FoundationInorganic nitrite (NO2
) was previously used extensively for
angina (1–3). Because of variable timing and predictability of
its effects, it fell out of favor when the faster acting and more
potent organic nitrates became available (4). High NO2

doses can produce vascular collapse and syncope (5); we and
others demonstrated recently that lower doses of sodiumInstitute, Cardiff University Medical School,
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, 2012; revised manuscript received March 9,nitrite (NaNO2) mediate vasodilation preferentially during
hypoxia (6,7). Thus, NaNO2 could exert clinically relevant
anti-ischemic effects at much lower doses than previously
used (8), while avoiding systemic adverse effects such as
hypotension and tachyphylaxis (9).
Few recent clinical studies have investigated NO2
, and
none have fully translated promising results from animal
models. Beetroot juice contains high levels of inorganic
nitrate (NO3
), which is bioconverted in the enterosalivary
circuit to NO2
, increasing plasma [NO2
] (10). Beetroot
concentrate enhances exercise performance in athletes
(11,12), reduces blood pressure (by about 10 mm Hg), and
attenuates ex vivo platelet activation in response to agonists
(13). Beetroot juice protected against endothelial dysfunc-
tion induced by ischemia-reperfusion (IR) in the human
Abbreviations
and Acronyms
FMD = ﬂow-mediated
dilation
IR = ischemia-reperfusion
NaNO2 = sodium nitrite
NO = nitric oxide
NO2
 = nitrite
NO3
 = nitrate
Vs = systolic velocity
JACC Vol. 61, No. 25, 2013 Ingram et al.
June 25, 2013:2534–41 Low-Dose Nitrite Attenuates Ischemia in Humans
2535forearm (14). Whether this was mediated by protective
effects of NO2
 during ischemia or reperfusion is unknown.
To determine the potential clinical value of low-dose
intravenous NO2
, we investigated 2 different models of
cardiovascular ischemic stress: ﬁrst, inducible myocardial
ischemia, in a double-blind, placebo-controlled study using
dobutamine stress echocardiography (15,16), and second,
forearm vascular IR injury, using ﬂow-mediated dilation
(FMD) to assess its pre-conditioning or post-conditioning
effect.
Methods
All patients and subjects were refrained from alcohol, caffeine,
and foods with high NO2
 or NO3
 content for 12 h before
each study and fasted during the study. In our previous
studies, this protocol minimized the inﬂuence of diet on
baseline plasma [NO2
]. Plasma [NO2
] is similar in healthy
control subjects and patients with stable coronary disease and
is not inﬂuenced by age or fasting (Table 1).
The protocols conformed to the Declaration of Helsinki
and were approved by the South East Wales Regional Ethics
Committee. Each subject gave written informed consent.
The dose of NaNO2 given was the same as we have used
previously (6). Either 1.5 mmol/min NaNO2 (Martindale
Pharmaceuticals, Brentwood, United Kingdom) or 0.9%
saline was administered by intravenous infusion for 20 min
into an antecubital vein. This regimen produces a peak
plasma [NO2
] level of about 350 nmol/l, approximately
doubling basal concentrations (Fig. 1). Plasma NO3
 and
methemoglobin do not change signiﬁcantly.
Study 1: myocardial ischemia. To test the hypothesis that
NaNO2 improves regional function selectively in ischemic
myocardial segments, we used myocardial velocity imaging
to quantify regional myocardial function during dobutamine
stress echocardiography in patients with known inducible
myocardial ischemia.
METHOD. Study patients had angina with ischemia docu-
mented by positive results on exercise tolerance tests (hori-
zontal ST-segment depression >1 mm) and were awaiting
revascularization for coronary artery disease conﬁrmed by
quantitative coronary arteriography (cross-sectional area
stenosis >70%). Exclusion criteria were unstable symptoms
requiring urgent treatment or ischemia on minimal exertion
(positive at stage I or II of a Bruce exercise test).Table 1 Plasma Concentrations of NO2
 in Healthy Controls and Pat
Subjects/Patients n Men/Women
Healthy controls 18 18/0
Stable coronary artery disease 36 28/8
Non–ST-segment elevation myocardial infarction 15 16/0
Healthy controls 28 14/14
Values are mean  SD. Ozone-based chemiluminescence (NO analyzer, NOA280i; Sievers, Boulder, Color
described previously (6,7,45).
NO ¼ nitric oxide; NO2 ¼ nitrite.STUDY DESIGN. A double-blind
crossover study was performed
(Fig. 2A). All subjects underwent
2 dobutamine stress echocardio-
graphic examinations, separated
by at least 7 days (mean interval:
10 days). They stopped all anti-
anginal medications for 48 h
before each study.
The protocol for each visit was
identical, apart from the infusion.
Either 1.5 mmol/min NaNO2 or
0.9% saline was started 10 min before the dobutamine
infusion and continued for 20 min in total, achieving peak
plasma NO2
 during the peak dose of dobutamine.
DOBUTAMINE STRESS ECHOCARDIOGRAPHY. A standard
dobutamine stress echocardiographic protocol was used (17).
Dobutamine was infused into a contralateral peripheral
arm vein at 5, 10, 20, 30, and 40 mg/kg/min each for 3 min
until the protocol was completed or the patient developed
symptoms. Atropine was not used.
A commercially available echocardiography system (Vivid
7, GE, Fairﬁeld, Connecticut) with a 2.5-MHz phased-array
transducer was used to obtain cross-sectional grayscale and
myocardial velocity images, with the subject in the left lateral
decubitus position. Loops recorded during passively held
end-expiration were stored digitally for post-processing using
an EchoPAC workstation (GE). Each subject rested for
30 min before baseline recordings. At each stage, apical
4-chamber, 2-chamber, and long-axis images were recorded
for 3 cardiac cycles. Image depth and width were optimized to
result in frame rates >120 frames/s.
Regional myocardial function was quantiﬁed from digitally
stored myocardial velocity loops, at the base of 6 left
ventricular “walls”: basal septal and basal lateral segments in
the apical 4-chamber view, basal anterior and basal inferior
in the 2-chamber view, and basal anteroseptal and basal
posterior in the long-axis view. Myocardial velocity was
measured at the base and strain rate in the middle of each
basal segment. Peak systolic velocity (Vs) was measured as
the maximal Vs occurring after isovolumic contraction.
Peak systolic strain rate was measured as the maximal strain
rate during ventricular systole. All measurements were per-
formed blinded to the study infusion and taken as the mean
of 2 beats.ients With Coronary Artery Disease
Age (yrs) Dietary Status Plasma NO2
 (nmol/l)
24.2  1.0 Overnight fast 189  11
58.5  9.8 Light breakfast 160  39
62.5  12.7 Light breakfast 188  33
43.3  14 Normal diet 163  15
ado) was used to detect NO liberated from plasma nitrite by tri-iodide reagent cleavage, as we have
Figure 1 Plasma NO2
 During the Infusion Protocol
Plasma nitrite (NO2
) reached a peak at 30 min and then declined, with a time to
half concentration of about 23 min, and was not signiﬁcantly different from
baseline at 55 min after cessation of the infusion (n ¼ 8 healthy subjects). NO2
was measured as described in Table 1 and as published previously in detail
(6,7,45). Values are mean  SEM.
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2536QUANTIFICATION OF MYOCARDIAL RESPONSES. The percent
increase of longitudinal Vs from baseline to peak-dose
dobutamine (in subjects receiving saline) was calculated
for each of the 6 basal wall segments in each subject. The
response of a normal, nonischemic myocardial segment is
an approximate doubling of Vs at peak stress (15); in this
study, segments exhibiting the highest percent increases in
Vs were taken to represent healthy myocardial segments,
and segments exhibiting the lowest proportional increases
in Vs were judged to demonstrate the greatest ischemic
burden.
Study 2: vascular model of IR injury. To test the hy-
pothesis that NO2
 protects against ischemic vascular injury,
as a pre-conditioning agent, we used an established model of
vascular IR injury with FMD as a measure of endothelial
function (18).
METHOD. Healthy subjects underwent high-resolution
ultrasonic assessment of brachial artery FMD before and
20 min after ipsilateral forearm ischemia created by inﬂating
an upper-arm cuff to suprasystolic pressure.
STUDY DESIGN. On separate visits, each subject received an
intravenous infusion into the contralateral arm (NaNO2 or
0.9% saline). This was given either before (pre-conditioning
study) (Fig. 2B) or during (post-conditioning study) (Fig.
2C) whole-arm ischemia.
FMD. Endothelial function was assessed at baseline using
FMD (19). Subjects lay supine in a temperature-controlled
room. A B-mode scan of the brachial artery was obtained
in the longitudinal axis, 5 to 10 cm above the antecubital
fossa (Aloka ProSound SSD-5500; Hitachi Aloka, Tokyo,
Japan). Electrocardiographically gated end-diastolic images
were acquired every 3 seconds for off-line analysis. A 1-cm
to 2-cm segment of artery was selected for measurement
of diameter, using automated edge detection software(Brachial Analyser for Research 5, Medical Imaging
Applications LLC, Coralville, Iowa). Blood velocity recor-
ded continuously at the center of the brachial artery using
pulsed Doppler was analyzed using the same software.
Arterial ﬂow was manipulated by a cuff placed around the
forearm immediately below the antecubital fossa. After 1 min
of baseline recording, the cuff was inﬂated to 250 mmHg for
5 min and then released, resulting in reactive hyperemia.
Arterial images were recorded for a further 5 min. Maximal
arterial diameter was determined and change from baseline
calculated and expressed as a percent age.
Transient whole-arm endothelial dysfunction was then
produced by inﬂating another cuff around the upper arm
to 250 mm Hg for 20 min. FMD was reassessed 20 min
after release of this cuff, with the difference from baseline
measurements representing the degree of injury resulting
from the IR stimulus.
Statistical analysis. These clinical proof-of-concept inves-
tigations were powered on the basis of published studies. In
our laboratory, the coefﬁcient of variation for repeated
measurements of myocardial Vs is about 10% (20), implying
that in 10 subjects, it should be possible to demonstrate
changes of 9% between repeated measurements at p < 0.05.
In 10 subjects, FMD demonstrated that beetroot juice
prevented endothelial dysfunction induced by a similar IR
protocol at similar plasma concentrations of NO2
 (14).
Increments of myocardial velocity during dobutamine
treatment are inﬂuenced by heart rate (15). We therefore
compared absolute peak responses and the rate of increase in
Vs adjusted for changes in heart rate.
Changes in longitudinal velocity in basal segments are
sensitive to the development of ischemia in any myocardial
segment (15). Measurements of velocity are more repro-
ducible than measurements of deformation (strain rate or
peak systolic strain). The mean percent increase in Vs in
ischemic segments at the peak dose of dobutamine is 50%
to 75%, compared with about 100% in nonischemic seg-
ments, but there is a continuum between ischemic and
healthy responses because of tethering between contiguous
segments. In this study, 6 basal segments were analyzed per
patient per visit; the 2 segments with the lowest responses
(in 89% of instances within or adjacent to the territory of
a coronary artery with a signiﬁcant stenosis) were compared
with the 2 segments with the highest responses (in the
territory of coronary arteries without angiographic stenosis).
The lower tertile represented the ischemia group and the
upper tertile the normal group.
Where appropriate, linear regression analysis was per-
formed comparing data from the pre-speciﬁed groups at
different stages of the protocol. The linear regression gradient
for each subject in each group was calculated. The resulting
mean linear regression gradients were compared using
repeated-measures analysis of variance with Newman-Keuls
post-tests, unless only 2 groups of data were present, in
which case paired t tests were used. Continuous variables are
reported as mean  SEM. Analyses were performed using
Figure 2 Myocardial Ischemia, Vascular Ischemic Pre-Conditioning, and Vascular Ischemic Post-Conditioning Studies
(A) Each subject underwent 2 separate stress echocardiographic examinations, during low-dose sodium nitrite (NaNO2) or 0.9% saline infusion, administered in double-blind
fashion in randomized order 10 days apart. (B) Either low-dose NaNO2 or 0.9% saline was given in randomized order (on separate visits) before inﬂation of the cuff around the
upper arm. (C) Either low-dose NaNO2 or 0.9% saline was given in randomized order (on separate visits) while the cuff was inﬂated around the upper arm. DSE ¼ dobutamine
stress echocardiography; FMD ¼ ﬂow-mediated dilation.
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2537GraphPad Prism version 4.0 (GraphPad Software, La Jolla,
California).
Results
Study 1: myocardial ischemia. Patient characteristics are
given inTable 2.Therewere no differences in heart rate or blood
pressure betweengroups (p¼NS) (details inOnlineAppendix).
Most dobutamine stress echocardiographic studieswere stopped
because of the onset of typical angina; the full protocol was
completed in 5 studies. No signiﬁcant adverse events occurred.
Velocity proﬁles from 55 of 60 myocardial walls (6 walls
in each of 10 subjects) were of sufﬁcient quality for analysis
of Vs throughout the study. Thus, the ischemic and control
groups each contained data from 18 basal segments.
In normal walls, Vs increased in response to dobutamine,
similarly during saline (þ117%) and NaNO2 (þ122%) (p ¼
NS) (Table 3, Fig. 3). In ischemicwalls, therewas an attenuated
increase during saline infusion (þ51%) but a normal increase
during NaNO2 infusion (þ132%). Similar changes were
observed in longitudinal systolic strain rate, which increased by79% and 66% in normal segments in response to dobutamine
during saline and NaNO2 infusions, respectively, whereas in
the abnormal segments, it increased by only 26% during saline
compared with 118% during NaNO2.
The change in Vs from baseline to peak dobutamine
in ischemic segments, adjusted for change in heart rate,
was þ3.7  0.6 cm/s/s during the control intervention
(ischemia/saline) and þ8.2  1.0 cm/s/s during NaNO2
infusion (ischemia/NO2
) (p < 0.01 vs. baseline, compa-
rable with normal segments). Responses to dobutamine
stress echocardiography in the healthy segments were not
inﬂuenced by NaNO2 (normal/saline: þ10.5  1.1 cm/s/s;
normal/NO2
: þ8.4  0.7 cm/s/s) (p ¼ NS, but p < 0.01
for each compared with the ischemia/saline group) (Fig. 3).
The mean linear regression gradient for the increase in Vs
relative to the increase in heart rate was 0.085  0.017 in the
ischemia/saline group. This was lower (p < 0.01) than in the
other groups (ischemia/NO2
: 0.132  0.015; normal/
saline: 0.164  0.019; normal/NO2: 0.140  0.011)
(Online Appendix).
Table 2
Demographics and Cardiovascular Disease Proﬁles of
the CAD Patients Recruited
N 10
Age (yrs) 56.2  4.2
Men/women 5/5
Weight (kg) 89.6  5.3
BMI (kg/m2) 30.9  1.3
Cardiac disease proﬁle
Single-vessel disease 7
2-vessel disease 3
Cross-sectional area stenosis (%) 93.9  1.9
Left ventricular ejection fraction (%) 55.6  2.0
Cardiovascular risk factors
Hypercholesterolemia 10
Total cholesterol (mmol/l) 5.4  0.5
Diabetes mellitus 4
Hypertension 6
Family history of premature CAD 3
Smoker (current or within the past 3 months) 4
Medications
Aspirin 10
Statins 10
b-blocker 7
Long-acting nitrates 4
Calcium-channel blocker 4
Clopidogrel 1
Nifedipine 1
Values are n or mean  SEM. Left ventricular ejection fraction was measured using the biplane
method of discs.
BMI ¼ body mass index; CAD ¼ coronary artery disease.
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2538Study 2: IR injury. The pre-conditioning protocol was
performed in 10 subjects (6 men) age 24.6  1.4 years, with
a mean body mass index of 23.7  0.9 kg/m2. When saline
was infused before the initiation of ischemia, peak FMD was
reduced on average by 42.6% after vascular ischemia (FMD
1 ¼ 6.8  0.7% vs. FMD 2 ¼ 3.9  0.7%; p < 0.01),
conﬁrming that the stimulus induced endothelial dysfunc-
tion (Table 4, Fig. 4). The IR injury was prevented when
NaNO2 infusion was delivered before the initiation of
ischemia (FMD 1 ¼ 5.9  0.7% vs. FMD 2 ¼ 5.2  0.5%;
p ¼ NS). There was no difference in baseline endothelial
function (FMD 1) between the two visits.
The post-conditioning protocol was performed in
9 subjects (5 men) age 27.7  2.0 years, with a mean body
mass index of 24.3  1.3 kg/m2. In this protocol, eachTable 3 Quantiﬁcation of Regional Myocardial Function During Dobu
Variable
Saline Infusion
Baseline Peak D
Normal walls
Basal segment Vs (cm/s) 5.80  0.28 12.60  0.44 6.79  0.27
Basal segment SR (s1) 1.46  0.13 2.61  0.34 1.15  0.36
Ischemic walls
Basal segment Vs (cm/s) 6.26  0.29 9.47  0.54 3.20  0.41
Basal segment SR (s1) 1.61  0.18 2.03  0.21 0.42  0.22
Values are mean  SD. Within-study comparisons were performed using paired t tests. For results of be
NaNO2 ¼ sodium nitrite; SR ¼ strain rate; Vs ¼ systolic velocity.infusion was started after initiation of ischemia (i.e., it was
delivered to the ischemic tissue during reperfusion). There
was a mean reduction in FMD of 35% after IR when saline
was administered (from FMD 1 ¼ 8.6  0.6% to FMD 2 ¼
5.6  1.0%; p < 0.05). The decrease in FMD after IR was
similar (41%) when NaNO2 was infused (from FMD 1 ¼
7.5  0.5% to FMD 2 ¼ 4.4  0.5%; p < 0.05) (Table 4).
Discussion
We demonstrated in 2 complementary clinical settings that
low-dose NaNO2 reduces the effects of ischemia, amelio-
rating inducible myocardial ischemia and protecting against
IR-mediated vascular injury, as long as it is administered
before the onset of ischemia.
In both clinical models, low-dose NO2
 was effective
when given intravenously for only 20 min, and its therapeutic
beneﬁts were demonstrable within 5 to 20 min. Local effects
were observed, without the systemic side effects associated
with organic nitrates and other nitric oxide (NO) donors.
Together, these studies imply that low-dose NaNO2 is most
useful if it is given before elective procedures such as coronary
artery bypass surgery, percutaneous coronary intervention,
and organ transplantation. It is less likely to be beneﬁcial if
initiated after the onset of ischemia.
NaNO2 as a targeted vasodilator. NaNO2 is a weak
vasodilator in normoxia, compared with other NO donors
such as glyceryl trinitrate (21). Previously, large doses of
NaNO2 given to patients with angina to achieve a quick
therapeutic response often produced profound and sustained
systemic vasodilation.
Our results demonstrate that low-dose NaNO2 can reduce
inducible myocardial ischemia in patients with stable
obstructive coronary artery disease, without inﬂuencing nor-
moxic vasculature. NaNO2 appears to act as a targeted coro-
nary vasodilator, providing an NO-like effect only in ischemic
regions. NO2
 exhibits vasoactivity mostly by reduction to
NO, via pathways that are exacerbated in hypoxia (7,22);
the principal candidates are deoxyhemoglobin (8), xanthine
oxidase (22), myoglobin (23), and aldehyde oxidase (24,25).
It remains unclear whether NO2
 reduction occurs primarily
in blood or tissue. Whether NO2
 acts selectively on
conductance or resistance vessels is also unclear and likely to
be a balance of pO2/HbO2 saturation, decreased pH, andtamine Stress Echocardiography
NaNO2 Infusion
p Value Baseline Peak D p Value
<0.01 5.67  0.28 12.58  0.56 6.91  0.53 <0.01
<0.01 1.39  0.13 2.31  0.14 0.92  0.18 <0.01
<0.01 5.32  0.34 12.36  0.58 7.03  0.54 <0.01
0.08 1.30  0.10 2.84  0.25 1.54  0.20 <0.01
tween-group comparisons, see the text.
Figure 3 Effect of NO2
 on Myocardial Responses
Comparison between normal and ischemic regions using the change in peak
systolic velocity (Vs) (baseline to peak-dose dobutamine) without (top) and with
(middle) correction for the change in heart rate (HR) and change in peak systolic
strain rate (SRs) (bottom) during dobutamine stress echocardiography.
NO2
 ¼ nitrite. *p < 0.05; ***p < 0.001.
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2539reductive state of oxidoreductase enzyme systems. NO2
 also
exhibits acute and direct vasodilation, most likely through
cyclooxygenase-mediated pathways (8).Table 4 Changes in FMD During Forearm Vascular Ischemia and Rep
Variable
Pre-Conditioning Protocol
First FMD Second FMD
Saline infusion
Diameter (mm) 3.73  0.21 3.76  0.21
Flow stimulus (%) 719  65 720  69
FMD (%) 6.8  0.7 3.9  0.7
NaNO2 infusion
Diameter (mm) 3.79  0.22 3.82  0.22
Flow stimulus (%) 763  79 841  64
FMD (%) 5.9  0.7 5.2  0.5
Values are mean  SD. Within-study comparisons shown in the table were performed using paired t test
measures analysis of variance with Newman-Keuls post-test). For results of between-group comparisons
FMD ¼ ﬂow-mediated dilation; NaNO2 ¼ sodium nitrite.Long-term low-dose NaNO2 supplementation may be an
effective alternative treatment for angina, given orally either
as NaNO2 itself, or as large doses of inorganic NO3
, which
is converted by oral bacteria to NO2
 (26,27). Beetroot
concentrate, high in NO3
, can increase plasma NO2
 to
about 800 nmol/l; much lower dietary intake of beetroot
concentrate elevates plasma NO2
 modestly, to levels similar
to those attained in our subjects. Importantly, plasma NO2

remains elevated for several hours after a single loading dose.
Organic nitrates are likely to remain the primary pharmaco-
logicmeans of achieving a rapidNO-mediated effect in clinical
practice, but long-term NaNO2 therapy might prevent toler-
ance (28). Primates given a continuous intravenous infusion
of NaNO2 for 14 days did not exhibit tachyphylaxis (29).
Study limitations. Our studies were not powered to address
the inﬂuence of diet and resulting plasma levels on acute
responses to NaNO2. However, we have not observed large
variations in plasma NO2
 across several populations unless it
was consumed during the previous 12 h. Plasma NO3
 varies
considerably more, and dietary consumption of large amounts
of NO3
 does have a direct inﬂuence on plasma NO2
 level,
and it can affect blood pressure and platelet responsiveness to
agonists (10,13,14,26,27). Our subjects were not fasting, but
they refrained from foods high in NO2
 or NO3
. The
question remains whether subjects with higher basal levels will
also beneﬁt from the modest elevation in NO2
 achieved by
the infusion we gave (to about 200 nmol/l).
Effects of NO2
L supplementation. Animal studies have
demonstrated a protective effect of long-term oral NaNO2
supplementation during experimental myocardial infarction
(30,31). The cardiovascular beneﬁts of a “healthy” Medi-
terranean diet and certain Chinese medicines could be partly
explained by an increase in NO2
 (32,33). Whether NaNO2
can improve clinical outcomes requires evaluation in
adequately powered, randomized clinical trials. It is possible
that long-term NaNO2 treatment could reduce clinical end
points where long-term augmentation of the endothelial
NO synthase–NO axis (with L-arginine) or long-term NO
donors (organic nitrates) has not. Uncoupling of endothelial
NO synthase and NO donors can produce other metabolites,
including the potentially harmful free radical peroxynitriteerfusion
Post-Conditioning Protocol
p Value First FMD Second FMD p Value
0.48 3.38  0.15 3.47  0.18 0.15
0.99 764  55 768  41 0.93
<0.01 8.6  0.6 5.6  1.0 <0.05
0.10 3.37  0.20 3.45  0.23 0.07
0.22 829  59 868  47 0.58
0.15 7.5  0.5 4.4  0.5 <0.01
s. In addition, no difference was present in ﬂow stimulus among all 4 protocols (p ¼ NS, repeated-
, see the text.
Figure 5
Potential Pathways Through Which NO2
 Affords
Protection Against Ischemic Insult
Downstream effects are considered largely due to nitrite reduction to nitric oxide
(NO) under stress conditions, but direct action on soluble guanylate cyclase (sGC)
and formation of S-nitrosothiol (SNO) are also evident. ATP ¼ adenosine
triphosphate; cGMP ¼ cyclic guanosine monophosphate; eNOS ¼ endothelial
nitric oxide synthase; NO2
 ¼ nitrite; PKG/C ¼ protein kinase G/protein kinase C.
Figure 4 Effect of Nitrite on IR Injury
Summary graph detailing the degree of endothelial dysfunction produced as
a result of the 2 ischemia-reperfusion (IR) protocols. FMD ¼ ﬂow-mediated dilation;
IPC ¼ ischemic pre-conditioning; IpostC ¼ ischemic post-conditioning;
NaNO2 ¼ sodium nitrite. *p < 0.01.
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2540(34). The efﬁcacy of NO donors depends on a healthy
endothelium and endothelial microenvironment, but endo-
thelial function deteriorates with age and increasing risk
factors. Administration of NaNO2 in this setting beneﬁted
patients with peripheral vascular diseases (35).
NaNO2 as a pre-conditioning but not a post-conditioning
agent. We showed that NaNO2 administered before an
ischemic insult protects against inducible endothelial dysfunction
after reperfusion. There was no protective effect when admin-
istered after the onset of ischemia, such that higher concentra-
tions of NaNO2 were delivered only during reperfusion.
Our results contradict those of Gonzalez et al. (36), who
reported that NaNO2 provided effective post-conditioning
in a canine acute myocardial infarction model. Myocardial
IR injury was reduced when high doses of NaNO2 were
given systemically during the ﬁnal 5 min of a 60-min period
of ligation of a coronary artery. This intervention increased
plasma NO2
 30-fold (to 6 mmol/l), greatly exceeding
plasma levels achieved in our studies. Alternative explana-
tions could be that such high levels lead to direct absorption
into ischemic myocardium from the left ventricular cavity,
adjacent perfused myocardium, or small collateral vessels,
activating protective pathways before reperfusion. An
intraventricular injection of NaNO2 given immediately
before reperfusion protected against injury in rats (37), but
most animal models have demonstrated beneﬁt when
NaNO2 was injected before ischemia (38–40).
Our “proof-of-concept” studies provide limited mecha-
nistic insights into howNaNO2 affords cytoprotection against
ischemic injury. Several potential pathways are summarized in
Figure 5. Most beneﬁts of NaNO2 are thought to derive from
its conversion toNO; activation of soluble guanylate cyclase or
protein kinase and mitochondrial adenosine triphosphate–
sensitive potassium channels limit adenosine triphosphate
depletion and mitochondrial calcium uptake (41). Further,
S-nitrosation of key intracellular proteins may reduce mito-
chondrial L-type Ca2þ channel function (42) and inhibit
complex 1 of the electron transport chain, which generatesreactive oxygen species during reperfusion (43,44). At the
modest and near-physiological doses of NaNO2 we used, we
cannot conﬁrm whether nitroglycerin-based and/or NO-
based cytoprotection observed at higher doses is also relevant.
We demonstrated previously that the vasoactivity of
NaNO2 during hypoxia does not depend on concurrent
elevation of plasma NO2
. After similar low doses in healthy
subjects, hypoxic pulmonary vasoconstrictionwas alleviated for
several hours despite plasma NO2
 returning to near-baseline
values (6). This implies that NO2
 enters the tissue and can be
used during hypoxia; or it is converted to a metabolite that is
stored in tissue; or its effect can be transmitted from the surface
of the vessel into tissue, where it prevents subsequent insult.
Conclusions
Low-dose NaNO2 reduced the effects of myocardial
ischemia in patients with stable coronary artery disease and
reduced vascular injury in healthy subjects when adminis-
tered before an IR insult. These effects occurred without
systemic vasodilation, suggesting that the beneﬁts of low-
dose NaNO2 are selectively targeted to ischemic myocar-
dium and vascular tissue. Thus, what has been considered
historically to be the weakest pharmacokinetic property of
NO2
 could turn out to be its greatest asset.
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